

Adenylate Kinase Enzyme Activity, Blood

# Overview

### **Useful For**

Assessment of adenylate kinase activity as part of the evaluation of chronic nonspherocytic hemolytic anemia

### **Method Name**

Only available as part of a profile. For more information see:

- -HAEV1 / Hemolytic Anemia Evaluation, Blood
- -EEEV1 / Red Blood Cell (RBC) Enzyme Evaluation, Blood

Kinetic Spectrophotometry (KS)

### **NY State Available**

Yes

# Specimen

## **Specimen Type**

Whole Blood ACD-B

### Specimen Required

Only available as part of a profile. For more information see:

- -HAEV1 / Hemolytic Anemia Evaluation, Blood
- -EEEV1 / Red Blood Cell (RBC) Enzyme Evaluation, Blood

### Reject Due To

Gross	Reject
hemolysis	

# **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Whole Blood ACD-B	Refrigerated	20 days	

# **Clinical & Interpretive**

#### **Clinical Information**

Adenylate kinase (AK) is a monomeric enzyme that catalyzes the nucleotide phosphoryl interconversion of adenosine triphosphate (ATP) and adenosine monophosphate (AMP) to 2 molecules of adenosine diphosphate (ADP). The level of



Adenylate Kinase Enzyme Activity, Blood

enzyme activity in neonates is normally mildly to moderately lower than in adults. AK deficiency (OMIM 612631) is a rare cause of autosomal recessive nonspherocytic hemolytic anemia.

Although rare, AK deficient-associated anemia has been described in multiple families of varied ethnic origin. Those individuals with heterozygous genetic alterations are predominantly asymptomatic and show a normal phenotype. Those individuals with homozygous or compound heterozygous genetic alterations display congenital chronic nonspherocytic hemolytic anemia (hemoglobin [Hb] levels of 8-9 g/dL) with hyperbilirubinemia and gallstones. Patients typically present at birth or in early childhood. Some patients have psychomotor impairment, although the pathogenesis is not well understood. Concurrent glucose 6-phosphate dehydrogenase (G6PD) deficiency exacerbates the anemia (Hb 6 g/dL). AK activity levels range from 0% to 44%, although most show less than 30% activity. Carriers have normal to only mildly decreased enzyme activity (1). Patients may respond well to splenectomy.

### **Reference Values**

Only available as part of a profile. For more information see:

- -HAEV1 / Hemolytic Anemia Evaluation, Blood
- -EEEV1 / Red Blood Cell (RBC) Enzyme Evaluation, Blood

> or =12 months: 195-276 U/g Hb

Reference values have not been established for patients who are younger than 12 months of age.

### Interpretation

In adenylate kinase deficiency, values are expected to be less than 30% of normal mean, although this value should be interpreted in the context of age of the patient and other enzyme values.

#### Cautions

Recent transfusion may mask the patient's intrinsic enzyme activity and cause unreliable results.

Adenylate kinase (AK) enzyme activity can normally be mildly to moderately decreased in neonates.

### **Clinical Reference**

- 1. Niizuma H, Kanno H, Sato A, Ogura H, Imaizumi M: Splenectomy resolves hemolytic anemia caused by adenylate kinase deficiency. Pediatr Int. 2017;59(2):228-230
- 2. Rapley S, Harris H. Red cell adenylate kinase activity in AK1 and AK 2-1 phenotypes. Annals of Human Genetics. 1970;33:361-364. doi:10.1111/j.1469-1809
- 3. Mohrenweiser HW. Frequency of enzyme deficiency variants in erythrocytes of newborn infants. Proc Natl Acad Sci U S A. 1981;78(8):5046-5050
- 4. Corrons JL, Garcia E, Tusell JJ, Varughese KI, West C, Beutler E. Red cell adenylate kinase deficiency: molecular study of 3 new mutations (118G>A, 190G>A, and GAC deletion) associated with hereditary nonspherocytic hemolytic anemia. Blood. 2003;102(1):353-356
- 5. Toren A., Brok-Simoni F, Ben-Bassat I, et al. Congenital haemolytic anaemia associated with adenylate kinase deficiency. Brit. J. Haemat. 1994;87:376-380
- 6. Bianchi P, Zappa M, Bredi E, et al. A case of complete adenylate kinase deficiency due to a nonsense mutation in AK-1 gene (arg107-to-stop, CGA-to-TGA) associated with chronic haemolytic anaemia. Brit. J. Haemat. 1999;105(1):75-79
- 7. Lachant NA, Zerez CR, Barredo J, et al. Hereditary erythrocyte adenylate kinase deficiency: A defect of multiple phosphotransferases? Blood. 1991;77(12):2774-2784
- 8. Koralkova P, van Solinge WW, van Wijk R. Rare hereditary red blood cell enzymopathies associated with hemolytic



Adenylate Kinase Enzyme Activity, Blood

anemia-pathophysiology, clinical aspects and laboratory diagnosis. Int J Lab Hematol. 2014;36:388-397

#### **Performance**

### **Method Description**

Adenylate kinase (myokinase) catalyzes the dismutation of adenosine diphosphate (ADP) into adenosine monophosphate and adenosine triphosphate. In this assay, the reverse reaction is measured by following the formation of ADP with pyruvate kinase and lactate dehydrogenase reactions resulting in 1,4-dihydronicotinamide adenine dinucleotide (NADH) being oxidized to NAD(+). The decrease in absorbance that occurs as NADH is oxidized is measured spectrophotometrically at 340 nm by an automated chemistry analyzer. (Beutler E: Red Cell Metabolism. A Manual of Biochemical Methods. 3rd ed. Grune and Stratton; 1984:93-95; van Solinge WW, van Wijk: Enzymes of the red blood cell. In: Rifai N, Horvath AR, Wittwer CT: eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:chap 30)

# **PDF** Report

No

# Day(s) Performed

Monday through Friday

### Report Available

5 days

### **Specimen Retention Time**

7 days

## **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

### Fees & Codes

### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### **CPT Code Information**

82657



Adenylate Kinase Enzyme Activity, Blood

# **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
AKC	Adenylate Kinase, B	44051-1

Result ID	Test Result Name	Result LOINC® Value
AKCL	Adenylate Kinase, B	44051-1